Veracyte, Inc.
VCYT
$46.16
-$0.23-0.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.82% | 13.75% | 18.20% | 20.81% | 28.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.82% | 13.75% | 18.20% | 20.81% | 28.58% |
| Cost of Revenue | 11.64% | 12.27% | 2.92% | 26.18% | 22.90% |
| Gross Profit | 14.72% | 14.37% | 25.56% | 18.51% | 31.09% |
| SG&A Expenses | 7.49% | 6.29% | 6.26% | 3.83% | 17.94% |
| Depreciation & Amortization | -12.33% | -13.25% | -12.21% | -20.91% | -28.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.31% | 6.32% | 5.30% | 9.09% | 18.78% |
| Operating Income | 83.71% | 161.98% | 290.67% | 334.38% | 298.01% |
| Income Before Tax | 12.11% | -83.02% | 489.31% | 111.30% | 156.59% |
| Income Tax Expenses | -114.65% | 37.06% | 965.91% | 23.36% | 1,199.35% |
| Earnings from Continuing Operations | 26.28% | -117.09% | 478.06% | 118.07% | 151.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.28% | -117.09% | 478.06% | 118.07% | 151.17% |
| EBIT | 83.71% | 161.98% | 290.67% | 334.38% | 298.01% |
| EBITDA | 53.74% | 76.78% | 880.41% | 372.60% | 76.07% |
| EPS Basic | 23.53% | -116.69% | 462.65% | 117.03% | 148.38% |
| Normalized Basic EPS | 44.73% | 147.54% | 918.70% | 298.61% | 221.14% |
| EPS Diluted | 26.32% | -117.86% | 461.45% | 115.84% | 146.34% |
| Normalized Diluted EPS | 45.71% | 149.40% | 898.37% | 286.81% | 215.23% |
| Average Basic Shares Outstanding | 2.22% | 2.42% | 4.37% | 6.16% | 5.78% |
| Average Diluted Shares Outstanding | 1.56% | 1.59% | 7.08% | 9.30% | 7.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |